BR1100108A - Agonista receptor como 5-ht1 para administração retal - Google Patents

Agonista receptor como 5-ht1 para administração retal

Info

Publication number
BR1100108A
BR1100108A BR1100108-9A BR1100108A BR1100108A BR 1100108 A BR1100108 A BR 1100108A BR 1100108 A BR1100108 A BR 1100108A BR 1100108 A BR1100108 A BR 1100108A
Authority
BR
Brazil
Prior art keywords
pct
receptor agonist
rectal administration
sec
date
Prior art date
Application number
BR1100108-9A
Other languages
English (en)
Inventor
Nadine Merlet
Isabelle Richard
Isabelle Thielemans
Original Assignee
Nadine Merlet
Isabelle Richard
Isabelle Thielemans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nadine Merlet, Isabelle Richard, Isabelle Thielemans filed Critical Nadine Merlet
Publication of BR1100108A publication Critical patent/BR1100108A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
BR1100108-9A 1992-05-07 1996-12-24 Agonista receptor como 5-ht1 para administração retal BR1100108A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929209882A GB9209882D0 (en) 1992-05-07 1992-05-07 Compositions

Publications (1)

Publication Number Publication Date
BR1100108A true BR1100108A (pt) 1999-12-07

Family

ID=10715158

Family Applications (1)

Application Number Title Priority Date Filing Date
BR1100108-9A BR1100108A (pt) 1992-05-07 1996-12-24 Agonista receptor como 5-ht1 para administração retal

Country Status (33)

Country Link
US (1) US5705506A (pt)
EP (1) EP0639072B1 (pt)
JP (1) JPH07506570A (pt)
KR (1) KR100253111B1 (pt)
AT (1) ATE163850T1 (pt)
AU (1) AU670083B2 (pt)
BE (1) BE1007024A5 (pt)
BG (1) BG62120B1 (pt)
BR (1) BR1100108A (pt)
CA (1) CA2135179C (pt)
CH (1) CH685920A5 (pt)
CY (1) CY2039B1 (pt)
CZ (1) CZ283512B6 (pt)
DE (1) DE69317418T2 (pt)
ES (1) ES2113533T3 (pt)
FR (1) FR2690847B1 (pt)
GB (2) GB9209882D0 (pt)
GR (1) GR3026584T3 (pt)
HK (1) HK95697A (pt)
HU (2) HU227338B1 (pt)
IE (1) IE75203B1 (pt)
IL (1) IL105468A (pt)
IT (1) IT1261471B (pt)
NO (1) NO306700B1 (pt)
NZ (1) NZ252132A (pt)
OA (1) OA10109A (pt)
RO (1) RO112993B1 (pt)
RU (1) RU2118527C1 (pt)
SG (1) SG46649A1 (pt)
TW (1) TW231970B (pt)
UA (1) UA37206C2 (pt)
WO (1) WO1993021916A1 (pt)
ZA (1) ZA933178B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044062A1 (en) * 1996-05-23 1997-11-27 Alcon Laboratories, Inc. The use of 5-ht1b/1d agonists to treat ocular pain
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
DK2198858T3 (da) * 1998-03-26 2011-10-03 Astellas Pharma Inc Præparat med opretholdt frigivelse af en makrolidforbindelse såsom tacrolimus
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
HUE031661T2 (en) 2010-10-15 2017-07-28 Contera Pharma Aps Combinations of serotonin receptor agonists for the treatment of movement disorders
US10561618B2 (en) 2012-04-18 2020-02-18 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ,インコーポレイテッド 医薬組成物
CN109689036A (zh) 2016-07-11 2019-04-26 康特拉医药公司 用于治疗早晨运动不能的脉冲药物输送系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197998A (en) * 1980-08-12 1985-08-16 Glaxo Group Ltd 5-amino(methyl)-1h-indol-3-ylalkaneamines
GB2082175B (en) * 1980-08-12 1984-05-02 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
GR79215B (pt) * 1982-06-07 1984-10-22 Glaxo Group Ltd
HU196752B (en) * 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
IT1181741B (it) * 1984-12-04 1987-09-30 Glaxo Group Ltd Derivati di indolo,procedimento per prepararli e composizioni farmaceutiche che li contengono
GB8431426D0 (en) * 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
US4833153A (en) * 1985-11-08 1989-05-23 Glaxo Group Limited Indole derivatives
PT88255B (pt) * 1987-08-13 1995-03-01 Glaxo Group Ltd Processo para a preparacao de derivados do indole
NZ238424A (en) * 1990-06-07 1993-12-23 Wellcome Found 3,5-substituted indole derivatives; medicaments and preparatory processes.

Also Published As

Publication number Publication date
RU2118527C1 (ru) 1998-09-10
AU4064093A (en) 1993-11-29
CA2135179C (en) 2000-12-05
IE930339A1 (en) 1993-11-17
GB2266665B (en) 1996-05-22
IL105468A0 (en) 1993-08-18
IE75203B1 (en) 1997-08-27
ES2113533T3 (es) 1998-05-01
TW231970B (pt) 1994-10-11
HU227338B1 (en) 2011-04-28
NZ252132A (en) 1996-09-25
NO944214D0 (no) 1994-11-04
AU670083B2 (en) 1996-07-04
JPH07506570A (ja) 1995-07-20
NO306700B1 (no) 1999-12-13
KR100253111B1 (en) 2000-07-01
BG99167A (bg) 1995-06-30
CH685920A5 (fr) 1995-11-15
EP0639072B1 (en) 1998-03-11
GB2266665A (en) 1993-11-10
FR2690847A1 (fr) 1993-11-12
CZ283512B6 (cs) 1998-04-15
DE69317418D1 (de) 1998-04-16
EP0639072A1 (en) 1995-02-22
IT1261471B (it) 1996-05-23
BG62120B1 (bg) 1999-03-31
NO944214L (no) 1994-11-07
BE1007024A5 (fr) 1995-02-21
DE69317418T2 (de) 1998-07-30
UA37206C2 (uk) 2001-05-15
HK95697A (en) 1997-08-08
FR2690847B1 (fr) 1995-06-09
CY2039B1 (en) 1998-04-30
GR3026584T3 (en) 1998-07-31
HU211638A9 (en) 1995-12-28
GB9309209D0 (en) 1993-06-16
RO112993B1 (ro) 1998-03-30
ZA933178B (en) 1994-01-10
US5705506A (en) 1998-01-06
CA2135179A1 (en) 1993-11-11
IL105468A (en) 1998-09-24
ATE163850T1 (de) 1998-03-15
OA10109A (en) 1996-12-18
SG46649A1 (en) 1998-02-20
HUT71418A (en) 1995-11-28
ITRM930286A0 (it) 1993-05-06
CZ272394A3 (en) 1995-10-18
GB9209882D0 (en) 1992-06-24
ITRM930286A1 (it) 1994-11-06
WO1993021916A1 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
YU2603A (sh) Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija
MX9702865A (es) Agentes estrogenicos.
BG105534A (en) 5ht1 means and method for the treatment of migraine
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
DK0850050T3 (da) Orale hurtigt-opløsende sammensætninger for dopaminagonister
BR1100108A (pt) Agonista receptor como 5-ht1 para administração retal
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
ZA971279B (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors
BR0306147A (pt) Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição
DK0485431T3 (da) Partielle agonister for det strychnin-ufølsomme glycin-modulations-site i N-methyl-D-aspartat-receptorkomplekset som neurofarmakologiske midler
SE9903995D0 (sv) New combination
ES2156444T3 (es) Nuevos compuestos.
ES2173871T3 (es) Tratamiento de condiciones neurologicas por un compuesto inhibidor de la interleukina-1.
FI950209A0 (fi) Farmakologisesti aktiiviset alfa-(tertiaarinen-amino-metyyli)-bentseenimetanolijohdannaiset
GR3024854T3 (en) Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances.
EP1051994A3 (en) 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
Elwood Dawn of a new era with substance P antagonists in depression?
SE9501773D0 (sv) New use
ECSP972049A (es) Derivados de lactama
ECSP972347A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas

Legal Events

Date Code Title Description
HHFK Processing applications according to articles 230 and 231 of law 9.279/96: republication
MT Patent procedure suspended until requirement met - articles 230 and 231 of law 9279/96
FGAN Processing applications according to articles 230 and 231 of law 9.279/96: granting
NB Patent issued - articles 230 and 231 of law 9279/96